Clinical Impact of the Predict Prostate Risk Communication Tool in Men Newly Diagnosed with Nonmetastatic Prostate Cancer: A Multicentre Randomised Controlled Trial
Publication: European Urology
David Thurtle, Val Jenkins, Alex Freeman, Mike Pearson, Gabriel Recchia, Priya Tamer, Kelly Leonard, Paul Pharoah, Jonathan Aning, Sanjeev Madaanh, Chee Goh, Serena Hilman, Stuart McCracken, Petre Cristian, lie, Henry Lazarowicz, Vincent Gnanapragasam
4 September 2021
Summary
Predict Prostate is a Cambridge developed and validated risk communication tool for men with a new prostate cancer diagnosis. It is a CE marked web tool and endorsed by NICE. In this multicentre RCT national study, researchers assessed the impact of this individualised risk communication tool, on patient decision-making after a diagnosis of localised prostate cancer.
Men were randomly assigned to two groups, which received either standard counselling and information, or this in addition to a structured presentation of the Predict Prostate tool. Men who saw the tool were less conflicted and uncertain in their decision-making, and recommended the tool highly. Those who saw the tool had more realistic perception about their long-term survival and the potential impact of treatment upon this.